全球惡性間皮瘤市場規模、佔有率、成長分析，依應用（醫院藥房、零售藥房）、依類型（口服、腸胃外）- 2024-2031 年行業預測

Global Malignant Mesothelioma Market Size, Share, Growth Analysis, By Application(Hospital Pharmacies, Retail Pharmacies), By Type(Oral, Parenteral) - Industry Forecast 2024-2031

出版日期: 2024年02月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球惡性間皮瘤市場規模為1.5393億美元，預計將從2023年的1.627億美元成長到2031年的2.5351億美元，預測期內（2024-2031年）複合CAGR為5.7%。

間皮瘤患者的計劃團體和支持網路是全球對抗這種癌症的關鍵支柱。他們的努力有助於提高認知、促進早期發現，並為患有間皮瘤的個人提供重要支持。這些組織透過其宣傳、教育措施和外展計劃發揮著不可或缺的作用，顯著改善了病患照護。透過向受疾病影響的人提供援助和資源，他們在減輕患者在困難道路上所面臨的負擔方面發揮關鍵作用。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical

簡介目錄

Product Code: SQMIG35A2572

Global Malignant Mesothelioma Market size was valued at USD 153.93 million in 2022 and is poised to grow from USD 162.70 million in 2023 to USD 253.51 million by 2031, growing at a CAGR of 5.7% in the forecast period (2024-2031).

Advocacy groups and support networks for mesothelioma patients serve as crucial pillars in the worldwide battle against this form of cancer. Their efforts are instrumental in raising awareness, promoting early detection, and furnishing vital support to individuals grappling with mesothelioma. These organizations fulfill an indispensable role through their advocacy, educational initiatives, and outreach programs, significantly enhancing patient care. By offering assistance and resources to those affected by the disease, they play a pivotal role in easing the burdens faced by patients on their difficult path.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malignant Mesothelioma Market Segmental Analysis

The global malignant mesothelioma market is segmented into three major segments i.e. by type, application, region. Based on type the market is segmented as, oral, parenteral. Based on application the market is segmented as, hospital pharmacies, retail pharmacies, oncology centers, other. Based on region the market is segmented as, North America, Europe, Asia-Pacific, MEA, and Latin America.

Drivers of the Malignant Mesothelioma Market

The surge in advancements in diagnostic methodologies plays a pivotal role in the detection of malignant mesothelioma cases. Significant enhancements in diagnostic techniques and tools have been witnessed over time, contributing to the early identification and diagnosis of this cancer. These improvements, coupled with heightened awareness among healthcare professionals and the public, have facilitated early detection and diagnosis, resulting in a higher reported incidence of cases at earlier stages.

Restraints in the Malignant Mesothelioma Market

A notable constraint in this context is the extended duration taken for diagnosis, which can impede timely intervention. Malignant mesothelioma is characterized by a prolonged latency period, often spanning several decades from initial asbestos exposure to symptom manifestation. This lengthy timeline poses a considerable challenge, delaying early diagnosis and intervention for individuals at risk.

Market Trends of the Malignant Mesothelioma Market

One of the key trends influencing the market is the aging population, which significantly contributes to the rising incidence of malignant mesothelioma. The cancer is more prevalent among older demographics, and with the global population aging, the likelihood of new cases is expected to increase. Moreover, the extended latency period for mesothelioma means that individuals exposed to asbestos earlier in life may develop the disease as they age.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Malignant Mesothelioma Market by Application

Market Overview
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Others

Global Malignant Mesothelioma Market by Type

Market Overview
Oral
Parenteral

Global Malignant Mesothelioma Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Corden Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Concordia International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Hakko Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Polaris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MolMed
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nichi-Iko Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments